在临床前阿尔茨海默氏症中,不受约束的定量磁化转移MRI对粉样蛋白负担的敏感性
Andrew Mao1,2,3, Sebastian Flassbeck1,2, Elisa Marchetto1,2
1Bernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology, New York University Grossman School of Medicine, New York, NY, USA.
概括
磁化转移MRI检测到粉样蛋白β,这是阿尔茨海默病 (AD) 的标志. 这种定量MT (qMT) 方法在没有放射性痕迹的情况下作为早期AD检测的生物标志物具有前途.
科学领域:
- 神经成像是一种神经成像.
- 生物标志物发现发现
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 磁化转移 (MT) MRI对大分子如粉样蛋白β敏感.
- 以前的研究使用了MT MRI来区分阿尔茨海默病 (AD) 患者与对照组.
- 粉样β积累是阿尔茨海默病的早期病理事件.
研究的目的:
- 调查一个不受约束的双池定量MT (qMT) 模型对临床前受试者粉样蛋白积累的敏感性.
- 评估qMT参数是否可以作为粉样β沉积的生物标志物.
- 为了比较qMT参数的灵敏度与皮质厚度测量.
主要方法:
- 在15名认知正常的志愿者中获得了12分钟的混合状态qMT扫描,具有1.24毫米的同位素分辨率 (由[18F]Florbetaben PET获得9个粉样蛋白阳性).
- 估计的不受约束的2池 qMT参数,包括汇率和半固体池纵向放松率 ().
- 进行了小组比较和与粉样蛋白PET SUVRs在叶片水平的相关性.
主要成果:
- 汇率和半固体池的 对粉样蛋白度敏感.
- 从结构性MRI获得的皮质厚度没有显示对粉样蛋白积累的敏感性.
- 汇率的变化与先前的临床AD发现一致;由于不受约束的建模,AD的变化是新的.
结论:
- 不受限制的定量MT (qMT) MRI参数,特别是汇率和
- qMTMRI显示出作为阿尔茨海默病中粉样蛋白病理学的非侵入性,无痕迹物替代生物标志物的潜力.
- 这种方法可以替代PET成像,用于检测早期的AD相关变化.
相关概念视频
Magnetic Resonance Imaging
5.1K
Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...
5.1K
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468


